Atara Biotherapeutics presented results showing that circulating EBV-targeted cytotoxic T lymphocyte
precursors could serve as a biomarker of clinical response to tab-cel in patients with EBV-driven diseases.
Induction of a [CD8.sup.+] cytotoxic T lymphocyte
response by cross-priming requires cognate CD4+ help.
In LTNP an immune response seems to occur with specific CD4 and CD8 T cells that control disease progression, in particular with highly active HIV-specific cytotoxic T lymphocyte
In the article titled "Epstein-Barr Virus-Induced Gene 3 (EBI3) Blocking Leads to Induce Antitumor Cytotoxic T Lymphocyte
Response and Suppress Tumor Growth in Colorectal Cancer by Bidirectional Reciprocal-Regulation STAT3 Signaling Pathway" , there were errors in the title, Introduction, Materials and Methods, and the legend of Figure 2, which should be corrected as follows:
In addition, cytotoxic T lymphocyte
antigen 4-blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation.
I read the recent publication on cytotoxic T lymphocyte
antigen-4 (CTLA-4) A49G polymorphism with a great interest (1).
In addition to stimulating B lymphocytes, Th2 cells suppress the cytotoxic T lymphocyte
response, decreasing the robustness of cell-mediated immunity.
Wicker of the University of Cambridge in England and her colleagues report that the presence of one variant of the gene corresponds with lowered production of the protein called cytotoxic T lymphocyte
The vaccinated animals had good CTL (cytotoxic T lymphocyte
) response after infection, stable CD4+ counts (T-cell counts), and CD4+ T cells that responded specifically to the infecting virus.
Acute rejection developed only in those with detectable levels of donor-specific cytotoxic T lymphocyte
precursors before conversion.
Diminished influenza A virus-specific MHC class I-restricted cytotoxic T lymphocyte
activity among elderly persons.
According to the company, Cytotoxic T lymphocyte
associated antigen 4 (CTLA-4), also known as CD152, is a transmembrane protein encoded by the CTLA-4 gene that can down-regulate the activity of T cells when binding with its ligands, B7.1 and B7.2, a pathway used by tumour cells to avoid T lymphocyte attack.